Table I.
Comparison among Pfizer/BioNTech BNT162b2 messenger RNA COVID-19 vaccine, Moderna messenger RNA-1273 SARS-CoV-2 vaccine, hepatitis B virus vaccine, and seasonal influenza vaccine
| Vaccines |
P vaccine |
M vaccine |
HBV vaccine |
Flu vaccine |
Vaccine comparison |
||||
|---|---|---|---|---|---|---|---|---|---|
| 14,649 |
10,403 |
58,063 |
152,627 |
P-M | P-HBV | P-Flu | M-HBV | M-Flu | |
| Total number of patients reporting SE | Number of reported SE (%) | Number of reported SE (%) | Number of reported SE (%) | Number of reported SE (%) | |||||
| Constitutional SE | |||||||||
| Headache | 2932 (20.02) | 2242 (21.55) | 3641 (6.27) | 11,594 (7.60) | .003 | <.001 | <.001 | <.001 | <.001 |
| Fatigue | 2188 (14.94) | 1537 (14.77) | 1124 (1.94) | 6305 (4.13) | .736 | <.001 | <.001 | <.001 | <.001 |
| Pyrexia | 2003 (13.67) | 1853 (17.81) | 9473 (16.32) | 19,880 (13.03) | <.001 | <.001 | .027 | <.001 | <.001 |
| Chills | 1985 (13.55) | 1763 (16.95) | 1291 (2.22) | 9890 (6.48) | <.001 | <.001 | <.001 | <.001 | <.001 |
| Pain | 1853 (12.65) | 1622 (15.59) | 3335 (5.74) | 18,395 (12.05) | <.001 | <.001 | .035 | <.001 | <.001 |
| Nausea | 1794 (12.25) | 1458 (14.02) | 3602 (6.20) | 9141 (5.99) | <.001 | <.001 | <.001 | <.001 | <.001 |
| Myalgia | 940 (6.42) | 721 (6.93) | 2669 (4.60) | 7004 (4.59) | .113 | <.001 | <.001 | <.001 | <.001 |
| Arthralgia | 754 (5.15) | 593 (5.70) | 2363 (4.07) | 4477 (2.93) | .059 | <.001 | <.001 | <.001 | <.001 |
| Malaise | 659 (4.50) | 290 (2.79) | 1683 (2.90) | 5246 (3.44) | <.001 | <.001 | <.001 | .554 | <.001 |
| Asthenia | 621 (4.24) | 433 (4.16) | 2645 (4.56) | 6407 (4.20) | .789 | .103 | .828 | .079 | .881 |
| Dermatologic SE | |||||||||
| Pruritus | 785 (5.36) | 678 (6.52) | 3651 (6.29) | 9197 (6.03) | <.001 | <.001 | .001 | .388 | .044 |
| Rash | 779 (5.32) | 528 (5.08) | 4954 (8.53) | 8305 (5.44) | .411 | <.001 | .540 | <.001 | .115 |
| Urticaria | 571 (3.90) | 403 (3.87) | 3715 (6.40) | 8424 (5.52) | .949 | <.001 | <.001 | <.001 | <.001 |
| Hyperhidrosis | 474 (3.24) | 314 (3.02) | 1190 (2.05) | 3225 (2.11) | .350 | <.001 | <.001 | <.001 | <.001 |
| Erythema | 416 (2.84) | 498 (4.79) | 1388 (2.39) | 12,426 (8.14) | <.001 | .001 | <.001 | <.001 | <.001 |
| Injection Site Pain | 1192 (8.14) | 1269 (12.20) | 3102 (5.34) | 18,140 (11.89) | <.001 | <.001 | <.001 | <.001 | .347 |
| Injection site erythema | 323 (2.20) | 1104 (10.61) | 2175 (3.75) | 17,523 (11.48) | <.001 | <.001 | <.001 | <.001 | .007 |
| Injection site swelling | 291 (1.99) | 839 (8.06) | 1358 (2.34) | 12,759 (8.36) | <.001 | .011 | <.001 | <.001 | .301 |
| Injection site warmth | 153 (1.04) | 576 (5.54) | 802 (1.38) | 7831 (5.13) | <.001 | .001 | <.001 | <.001 | .073 |
Values in bold are values that are statistically significant (P value <.05). Cutoff value for statistical significance ≤.05.
Flu, Seasonal influenza vaccine; HBV, hepatitis B virus vaccine; M, Moderna messenger RNA-1273 SARS-CoV-2 vaccine; P, Pfizer/BioNTech BNT162b2 messenger RNA COVID-19 vaccine; SE, side effect.